TREATMENT
HER2 Amplification May Predict Resistance to Anti-EGFR Therapy in Metastatic Colorectal Cancer — ESMO Gastrointestinal Oncology
An exploratory analysis from the CAPRI-2 GOIM trial examined HER2 gene alterations in patients with RAS/BRAF wild-type, microsatellite stable metastatic colorectal cancer treated with FOLFIRI chemotherapy plus cetuximab (an anti-EGFR antibody). Researchers found that HER2 amplification or mutation may be associated with poorer response to anti-EGFR therapy, suggesting HER2 testing could help identify patients unlikely to benefit from this treatment approach.
What this means
If you're considering anti-EGFR therapy like cetuximab or panitumumab, ask whether your tumor has been tested for HER2 alterations. If HER2 is amplified or mutated, you may benefit from HER2-targeted therapies instead, which are increasingly available in clinical trials.